Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT‐AF Registry
Emil Loldrup Fosbøl(University of Copenhagen), Jonathan P. Piccini(Clinical Research Institute), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Laine Thomas(Duke University), Roger M. Mills(Janssen (Belgium)), Peter R. Kowey(Lankenau Institute for Medical Research), DaJuanicia N. Holmes(Duke University), Eric D. Peterson(The University of Texas Southwestern Medical Center), Bernard J. Gersh(Clinical Research Institute), James A. Reiffel(St. John's University)
Cited by 69
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k